DrugPatentWatch Database Preview

Litigation Details for Spectrum Pharmaceuticals, Inc. v. Sandoz Inc. (D. Nev. 2012)

« Back to Dashboard

Spectrum Pharmaceuticals, Inc. v. Sandoz Inc. (D. Nev. 2012)

Docket		Date Filed	2012-01-19
Court	District Court, D. Nevada	Date Terminated	2015-02-19
Cause	35:271 Patent Infringement	Assigned To	Gloria Maria Navarro
Jury Demand		Referred To	Nancy J. Koppe
Patents	6,500,829
Link to Docket	External link to docket

Details for Spectrum Pharmaceuticals, Inc. v. Sandoz Inc. (D. Nev. 2012)

Date Filed	Document No.	Description	Snippet	Link To Document
2014-12-28	313		continuation 12 applications. (See U.S. Patent No. 6,500,829). The ’829 Patent issued with fourteen (14) 13 …commonly used chemotherapy agent. U.S. Patent No. 22 6,500,829 col.1 ll.22–24 (filed Apr. 18, 1995). …amount of 25 2000 mg per dose.” See U.S. Patent No. 6,500,829 col.9 ll.55, 63–64. This Court construed…administered in divided 6 dose.” U.S. Patent No. 6,500,829 col.5 ll.15–21. This portion of the specification…granted on October 2, 5 2012. (See U.S. Patent No. 6,500,829). 6 Defendant asserts that Plaintiffs	External link to document
2015-02-24	368		18 of claims 1 and 2 of U.S. Patent No. 6,500,829 (the “’829 patent”). Having considered the 19 parties…inventors of the ’829 patent also obtained U.S. Patent No. 4,959,472 (the “’472 4 patent”), which is directed…Cosulich ’018 Patent (PTX 15) 16 91. U.S. Patent No. 2,688,018 (the “’018 patent”) issued on August… regarding the ’829 patent, which asserts that the claims of the 18 ’829 patent are invalid, unenforceable…)). 23 B. THE ’829 PATENT 24 27. The ’829 patent is titled “Substantially Pure Diastereoisomers	External link to document